

Monoclonal Antibody Production and Cross Department Process Optimization Strategy

Shilei Sun^{1*}, Wei Ma²

¹ Shanghai Junshi Biotechnology Co., Ltd, Shanghai, China

² Rieckermann Industrial Technologies (Shanghai) Co., Ltd, Shanghai, China

Email Address

sunshilei0628@163.com (Shilei Sun), xmgmw@163.com (Wei Ma)

*Correspondence: sunshilei0628@163.com

Received: 15 May 2024; Accepted: 30 May 2024; Published: 26 June 2024

Abstract:

This paper discusses the importance of monoclonal antibody products in the field of biomedicine and the challenges faced in the production process, especially the optimization of cross sectoral processes. As an important part of the field of biomedicine, the production efficiency and quality control of monoclonal antibody products are directly related to the market competitiveness of enterprises and the therapeutic effect of patients. This paper first analyzes the production process of monoclonal antibody products, including the upstream cell culture and fermentation process and the downstream purification and preparation process. Then, it reveals the problems existing in the current cross departmental process, such as the poor connection between R&D, production and quality control, the lack of coordination between material procurement, warehousing and logistics, the mismatch between production process and equipment selection, and the low efficiency of information communication and decision-making implementation. To solve these problems, a series of cross department process optimization strategies were proposed, including establishing cross department coordination mechanism, optimizing material management, improving production process and equipment, and strengthening quality control and inspection. These strategies aim to improve the production efficiency and quality of monoclonal antibody products, so as to enhance the market competitiveness of enterprises and better serve the majority of patients.

Keywords:

Monoclonal Antibody Products, Biomedicine, Production Process, Cross Department Collaboration, Material Management

1. Introduction

Monoclonal antibody (mAb) products, as a bright pearl in the field of biomedicine, have shown outstanding application value in disease diagnosis and treatment since its inception. Monoclonal antibody (mAb) refers to the uniform antibody produced by a single B lymphocyte clone against a specific antigen epitope. Its high specificity and affinity make monoclonal antibodies widely used in the field of biomedicine, such as

targeted therapy, immune detection, disease prevention and so on. Especially in the fields of anti-tumor and autoimmune diseases, monoclonal antibody drugs have become an indispensable treatment method, which significantly improves the quality of life and survival time of patients. The emergence of monoclonal antibody drugs is a revolution in the field of biomedicine. They can accurately recognize and bind specific antigens, so as to achieve the purpose of treating or preventing diseases. Compared with traditional drug therapy, monoclonal antibody drugs have higher selectivity and lower side effects, so they have been widely used and recognized in clinic. With the continuous development of biotechnology, more and more monoclonal antibody drugs have been developed, which has made great contributions to human health.

However, the production process of monoclonal antibody products is not smooth. First of all, the production technology is complex and expensive, requiring highly specialized equipment and technical personnel, which undoubtedly increases the difficulty and cost of production. Secondly, the quality control in the production process is very important, because any minor error may lead to unqualified products and even threaten the health of patients. In addition, the stability and storage conditions of monoclonal antibody products are also extremely harsh, and they need to be stored under specific temperature, humidity and light conditions to ensure their activity and safety. In addition to the above production and technical challenges, monoclonal antibody products are also facing the dual pressures of market competition and policies and regulations. With more and more biomedical companies entering this field, the market competition is increasingly fierce. At the same time, governments around the world are also increasingly strict in the regulation of biomedical products, requiring enterprises to continuously improve product quality and safety. These challenges make the production and research and development of monoclonal antibody products more complex and difficult.

Facing many challenges in the production process of monoclonal antibody products, cross departmental process optimization is particularly important. First of all, by optimizing the cross departmental process, we can strengthen the communication and cooperation between R&D, production, quality control and other departments, so as to improve the production efficiency and quality. This optimization is helpful to break the departmental barriers and realize the rational allocation and efficient utilization of resources. Secondly, cross departmental process optimization helps to reduce production costs and risks. By simplifying the process, reducing redundant links and avoiding resource waste, enterprises can reduce production costs while ensuring product quality. In addition, optimizing the process can also improve the risk response ability of enterprises and reduce the uncertainty and potential risks in the production process. Finally, cross departmental process optimization is of great significance to enhance the market competitiveness of enterprises. In the field of biomedicine, product quality and production efficiency are the key factors of enterprise competitiveness. By optimizing the process, enterprises can respond to market demand faster, improve customer satisfaction, and stand out in the fierce market competition. At the same time, optimizing the process also helps enterprises better adapt to changes in policies and regulations and ensure product compliance and safety.

2. Analysis of Monoclonal Antibody Production Process

The production of monoclonal antibody products is a complex and delicate process, involving multiple links and steps. The production process of monoclonal antibody

products, including upstream process and downstream process, will be analyzed in detail below.

2.1. Upstream process: cell culture and fermentation

The upstream process mainly focuses on cell culture and fermentation, which is the basis and core of monoclonal antibody production.

(1) Development and optimization of cell lines

Cell line is the key to the production of monoclonal antibody. When selecting cell lines, we need to consider their growth rate, product expression, stability and adaptability to culture conditions. In order to obtain high-yield and stable cell lines, a lot of screening and optimization work is usually needed. This includes genetic engineering of cell lines to improve their ability to express monoclonal antibodies; At the same time, it is also necessary to test the stability of cell lines to ensure that they can maintain a stable yield and quality of monoclonal antibodies in the long-term culture process.

In the process of optimizing cell lines, various technical means may be used, such as gene editing, flow cytometry and so on, in order to achieve the precise transformation and screening of cell lines. The application of these techniques not only improved the development efficiency of cell lines, but also laid a solid foundation for the subsequent production of monoclonal antibodies.

(2) Selection and optimization of culture medium

Culture medium is an important basis for cell growth and monoclonal antibody expression. When selecting the culture medium, the effects of nutrients, pH, osmotic pressure and other factors on cell growth and monoclonal antibody expression should be considered. In order to obtain the best culture effect, it is usually necessary to optimize the culture medium. This includes adjusting the composition of the culture medium to meet the needs of cell growth and monoclonal antibody expression; At the same time, it is also necessary to accurately control the pH value and osmotic pressure of the medium to ensure the normal growth of cells and the stable expression of monoclonal antibodies.

(3) Monitoring and control of fermentation process

The monitoring and control of fermentation process is the key link to ensure the yield of monoclonal antibody. In the fermentation process, it is necessary to monitor the cell density, monoclonal antibody concentration, dissolved oxygen and other key parameters in real time, and adjust the fermentation conditions in time according to the monitoring results, so as to ensure the optimal growth state of cells and high-yield expression of monoclonal antibody. In order to achieve this goal, various advanced biosensors and automation technologies are usually used to improve the controllability and efficiency of the fermentation process.

2.2. Downstream process: purification and preparation

The downstream process mainly focuses on the purification and preparation of monoclonal antibody, which is a key step to ensure the quality and safety of monoclonal antibody products.

(1) Preliminary purification and fine purification

The primary purification is mainly to remove pollutants such as cell debris, impurities and host cell proteins, and lay the foundation for subsequent fine purification. The preliminary purification methods include physical methods such as centrifugation and filtration, and chemical methods such as ion exchange chromatography. The application of these methods can effectively improve the purity of monoclonal antibody and reduce its impurity content.

Fine purification is to further improve the purity of monoclonal antibody and remove residual impurities and pollutants. Fine purification methods include affinity chromatography, gel filtration chromatography and other advanced separation technologies. The application of these technologies can realize the efficient separation and purification of monoclonal antibodies, so as to obtain high-purity monoclonal antibody products.

(2) Virus inactivation and removal

Virus contamination is a potential risk in the production of monoclonal antibodies. In order to ensure the safety of monoclonal antibody products, it is usually necessary to inactivate and remove the virus. This includes heat treatment of monoclonal antibodies or the use of specific chemical reagents to inactivate the virus; At the same time, ultrafiltration, nanomembrane filtration and other technologies can also be used to remove virus particles. The application of these measures can effectively reduce the risk of virus contamination and improve the safety of monoclonal antibody products.

(3) Formulation and filling of preparations

Formulation is one of the final steps of monoclonal antibody products. In the process of formulation, the stability, solubility and route of administration of monoclonal antibody should be considered. In order to ensure the stability and effectiveness of monoclonal antibody products, the formulation is usually optimized and adjusted. This includes the selection of buffer solution, stabilizer, preservative and other components and the determination of addition amount; At the same time, the pH value, osmotic pressure and other parameters of the preparation need to be accurately controlled to meet the needs of clinical use.

The filling process is to pack the monoclonal antibody products into appropriate containers for storage and transportation. During the filling process, it is necessary to ensure the cleanness and sterility of the container to avoid pollution; At the same time, it is also necessary to accurately control the filling volume to ensure that the dose of each bottle of monoclonal antibody product is accurate. In addition, it is also necessary to check the quality of the filled monoclonal antibody products to ensure that they meet the relevant standards and requirements.

3. Status Quo and Problem Analysis of Cross Department Process

In the production process of monoclonal antibody products, cross sectoral cooperation is crucial. However, in practice, we often encounter various problems, which affect production efficiency, product quality and enterprise profits. The following is a detailed analysis of the current situation and existing problems of cross departmental processes.

3.1. Connection between R&D, production and quality control

The link between R&D department, production department and quality control department is the key link in the production process of monoclonal antibody products.

However, in practice, the connection between the three departments is often not smooth.

First, when developing new products, the R&D department may pay too much attention to technological innovation and ignore the feasibility of production process and the difficulty of quality control. As a result, when taking over new products, the production department needs to spend a lot of time and energy on process adjustment and optimization, and may even need to transform the equipment, which seriously affects the production efficiency.

Secondly, there are also problems in the timing and mode of intervention of the quality control department in the production process. If the intervention is too early, it may interfere with the innovation activities of the R&D department; If the intervention is too late, the product quality problems may not be found and corrected in time. In addition, there may be differences in quality standards and inspection methods between the quality control department and the production department, resulting in differences and disputes in inspection results.

3.2. Coordination of material procurement, warehousing and logistics

In the production process of monoclonal antibody products, the coordination of material procurement, warehousing and logistics is also crucial. However, at present, there are many problems in the coordination among the three links.

First, the material purchasing department may not be able to accurately predict the production demand, resulting in excessive or insufficient material inventory. Excessive inventory will increase storage costs and management difficulties, while insufficient inventory may lead to production interruption. In addition, there may be problems in the communication and coordination between the procurement department and the supplier, such as the supplier's untimely delivery and unstable quality.

Secondly, in terms of warehouse management, there may be problems such as disorderly placement of goods and unclear identification, resulting in errors in material receiving and distribution. At the same time, the control of storage environment is also very important, such as temperature, humidity and other environmental factors may affect the quality and stability of materials. If the storage management is not good, the materials will be damaged or deteriorated, which will affect the product quality and production efficiency.

Finally, in the logistics link, there may be problems such as improper selection of transportation mode, damage or loss of goods during transportation. These problems will not only increase the logistics cost, but also affect the production schedule and customer satisfaction.

3.3. Matching between production process and equipment selection

In the production process of monoclonal antibody products, the matching of production process and equipment selection is very important. However, in practice, there is often a mismatch between the two.

First, the complexity and particularity of the production process may put forward specific requirements for the equipment. If the equipment is improperly selected or cannot meet the needs of production process, it will lead to problems such as low production efficiency and unstable product quality. For example, some specific

production processes may require high-precision temperature control systems or special mixing equipment. If the equipment selection does not meet the requirements, the production effect will be seriously affected.

Secondly, the performance and maintenance of the equipment may also affect the implementation of the production process. If the equipment performance is unstable or the maintenance is improper, it will lead to problems such as failure or shutdown in the production process, which will affect the production progress and product quality.

3.4. Efficiency of information communication and decision execution

In the production process of monoclonal antibody products, the efficiency of information communication and decision execution is also crucial. However, there are often problems in these two aspects.

First of all, there may be problems in information communication, such as poor information and untimely transmission. This may lead to the failure of each department to timely understand the production progress, quality problems and other key information, which will affect the production efficiency and product quality. In order to solve these problems, enterprises need to establish a perfect information communication mechanism to ensure the timely and accurate transmission of key information between departments. At the same time, we can also consider introducing information management system to improve the efficiency and accuracy of information transmission.

Secondly, in terms of decision-making implementation, there may be problems such as slow decision-making and ineffective implementation. This may lead to problems in the production process that cannot be solved in time, and then affect the production schedule and enterprise profits. In order to improve the efficiency of decision execution, enterprises need to strengthen the optimization of decision process and the improvement of execution. A rapid response mechanism can be established to deal with unexpected problems in the production process and ensure that decisions can be implemented quickly and effectively.

4. Cross Department Process Optimization Strategy

In the production process of monoclonal antibody products, the optimization of cross departmental process is of great significance to improve the production efficiency, product quality and market competitiveness of enterprises. In order to realize the optimization of cross department process, enterprises need to adopt a series of strategies to strengthen the cooperation between departments, optimize material management, improve production process and equipment, and strengthen quality control and inspection. The following is a detailed description of these strategies.

4.1. Establish cross departmental coordination mechanism

The establishment of cross department collaboration mechanism is the key to realize cross department process optimization. Enterprises need to clarify the responsibilities and division of labor of each department, strengthen regular communication and information sharing, and develop cross departmental collaboration processes and specifications.

- (1) Clarify the responsibilities and division of labor of each department

First of all, the enterprise should clarify the responsibilities and division of labor of each department to avoid overlapping or omission. Each department should be clear about its work content and scope of responsibility, so as to better coordinate and cooperate. At the same time, enterprises should establish a accountability mechanism to ensure that all departments can conscientiously perform their duties and improve work efficiency.

(2) Strengthen regular communication and information sharing

In order to achieve effective collaboration across departments, enterprises need to strengthen communication and information sharing among departments. Cross department meetings can be held regularly to discuss key information such as production progress and quality problems, and jointly solve problems. In addition, modern information technology means, such as internal communication tools and shared databases, can also be used to realize real-time transmission and sharing of information and improve communication efficiency.

(3) Develop cross departmental collaboration processes and specifications

Enterprises need to formulate clear cross departmental collaboration processes and specifications to ensure the smooth cooperation between departments. These processes and specifications should include collaborative steps, time nodes, responsible persons and other elements to ensure the orderly progress of the work. At the same time, enterprises should also establish corresponding assessment mechanisms to evaluate, reward and punish the effectiveness of cross departmental cooperation.

4.2. Optimize material management

Material management is an important link in the production process of monoclonal antibody products. Optimizing material management can improve production efficiency, reduce inventory costs and ensure the quality of materials.

(1) Establish a strict supplier audit and material inspection system

The enterprise shall establish a strict supplier audit system to ensure that the purchased materials meet the production requirements. At the same time, it is also necessary to establish a perfect material inspection system to inspect and control the quality of incoming materials to ensure that the quality of materials meets the standards. This helps to ensure the quality of products from the source.

(2) Realize the collaboration between material requirement plan and purchase plan

Enterprises need to realize the collaboration between material demand planning and purchase planning to ensure that the supply of materials can meet the production demand. The production department shall formulate the material demand plan according to the production plan and communicate closely with the procurement department to ensure that the procurement plan can accurately reflect the production demand. This can avoid material shortage or surplus and improve production efficiency.

(3) Improve warehousing and logistics efficiency

Enterprises need to improve the efficiency of warehousing and logistics to ensure that materials can be delivered to the production site timely and accurately. This goal can be achieved by introducing advanced warehouse management system and

logistics technology. For example, the Internet of things technology is used to track and monitor materials in real time to ensure the safety and timely delivery of materials. At the same time, enterprises should also optimize the storage layout and management process to improve the efficiency and accuracy of material storage and storage.

4.3. Improve production process and equipment

The improvement of production process and equipment can improve production efficiency, reduce production costs and ensure product quality. Enterprises need to pay attention to the introduction of advanced technology and equipment, equipment maintenance and repair, and skill training of production personnel.

(1) Introduce advanced technology and equipment to improve production efficiency

Enterprises should pay attention to the latest technology and equipment trends in the industry, and timely introduce advanced production processes and equipment to improve production efficiency. For example, the introduction of automated production lines and intelligent equipment can reduce manual operation and improve production speed and accuracy. At the same time, the introduction of new technologies and equipment can also reduce production costs and improve the market competitiveness of enterprises.

(2) Strengthen equipment maintenance to reduce failure rate

The stable operation of equipment is the key to ensure production efficiency. Enterprises need to establish a sound equipment maintenance and repair system, and regularly inspect, repair and maintain the equipment. This can extend the service life of the equipment, reduce the failure rate and improve the production efficiency. At the same time, the enterprise should also establish an emergency plan for equipment failure to ensure timely response and solve problems in case of equipment failure.

3) Regular skill training for production personnel

The skill level of production personnel has an important impact on production efficiency and product quality. Enterprises need to regularly carry out skill training for production personnel to improve their operation level and quality awareness. The training contents include but are not limited to equipment operation, process flow, quality control, etc. Through skill training, the professional quality and work efficiency of production personnel can be improved, and then the overall production level of enterprises can be improved.

4.4. Strengthen quality control and inspection

Quality control and inspection are the key links in the production process of monoclonal antibody products. Enterprises need to establish a sound quality management system, strengthen process monitoring and finished product inspection, timely feed back quality problems and continue to improve.

(1) Establish a perfect quality management system

Enterprises need to establish a sound quality management system and clarify quality standards and inspection processes. This can ensure that the product is always in a controlled state in the production process, and ensure that the quality of the product meets the standards. At the same time, the enterprise should also establish a quality traceability system to trace the production process of products and the source of raw materials, so as to find and solve problems in time.

(2) Strengthen process monitoring and finished product inspection

Enterprises need to strengthen the monitoring of the production process and the inspection of finished products. The advanced detection equipment and technology can be used to carry out real-time monitoring and data acquisition of key control points in the production process to ensure that the production process is under control. At the same time, conduct comprehensive quality inspection and control on the finished products to ensure that the quality of the products meets the standards and customer requirements. Unqualified products shall be isolated and treated in time to prevent adverse effects from entering the market.

(3) Timely feedback quality problems and continuous improvement

Enterprises need to establish a quality problem feedback and continuous improvement mechanism. When quality problems are found, feedback and cause analysis shall be carried out in time, corresponding improvement measures shall be formulated and the verification effect shall be tracked. At the same time, enterprises should also encourage employees to actively participate in quality improvement activities, put forward improvement opinions and suggestions, and jointly promote the continuous improvement of product quality.

5. Conclusions

As an important part of the field of biomedicine, the production efficiency and quality control of monoclonal antibody products are directly related to the competitiveness of enterprises and the well-being of patients. Through the in-depth study of the cross departmental collaborative work in the production process of monoclonal antibody products, it is not difficult to find that the current problems such as poor process convergence, collaboration problems and information communication barriers restrict the production efficiency and quality of monoclonal antibody products to varying degrees.

This paper analyzes several key links in the production process of monoclonal antibody products in detail, and puts forward targeted cross departmental process optimization strategies. Through the establishment of cross departmental coordination mechanism, optimization of material management, improvement of production process and equipment, and strengthening of quality control and inspection, it is expected to significantly improve the production efficiency of monoclonal antibody products and ensure product quality, so as to enhance the market competitiveness of enterprises and better serve the majority of patients.

Looking forward to the future, with the continuous progress of biomedical technology and the intensification of market competition, the production of monoclonal antibody products will face more challenges and opportunities. Enterprises need to continue to pay attention to industry trends, timely introduce new technologies and equipment, and constantly optimize production processes to adapt to the changing market demand. At the same time, strengthening internal management and improving team cooperation efficiency are also the key to ensure the production efficiency and quality of monoclonal antibody products. We believe that through continuous efforts and innovation, the production of monoclonal antibody products will usher in a better tomorrow and make greater contributions to the cause of human health.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

References

- [1] Yu, H.; Wu, W. Optimal design of process-oriented production planning department management in PT company. *Enterprise Reform and Management*, 2019, 19, 40-42.
- [2] Zhang, P. Research and optimal design of production and marketing collaboration in G company (Doctoral dissertation, Shandong University). 2018.
- [3] Jiang, H. Research on the optimization of construction waste management process (Doctoral dissertation, Jinan University). 2016.
- [4] Sui, L. Optimization idea of university functional department management based on process management. *Science and Technology Vision*, 2016, 04, 154-155.
- [5] Fu, K. Research on optimization scheme and effect of production site management in J company of photovoltaic manufacturing industry (Doctoral dissertation, Nanjing Agricultural University). 2015.
- [6] Duan, Y.; Wang, Y. From “functional type” to “process type”: Shijiazhuang Mobile optimizes the establishment of a cross-department physical closed-loop management process. *Telecommunications Enterprise Management*, 2011, 09, 52-53.



© 2024 by the author(s); licensee International Technology and Science Publications (ITS), this work for open access publication is under the Creative Commons Attribution International License (CC BY 4.0). (<http://creativecommons.org/licenses/by/4.0/>)